-

$undefined

N/A

(N/A)

Orchard Therapeutics NASDAQ:ORTX 01/24/24- Company acquired by Kyowa Kirin. Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. The company's ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSK's rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Location: London, EC4N 6EU, United Kingdom | Website: www.orchard-tx.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Short % of Float

0.03%

Insider Ownership

12.21%

Institutional Own.

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Lenmeldy (atidarsagene autotemcel) (OTL-200) (ex vivo autologous gene therapy) Details Rare diseases, Rare genetic disease, Metachromatic leukodystrophy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTL-203 (ex vivo autologous gene therapy) Details Metabolic disorder, Mucopolysaccharidosis Type 1	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTL-201 (ex vivo autologous gene therapy) Details Metabolic disorder, Eye disease , Mucopolysaccharidosis type IIIA, Sanfilippo Syndrome	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTL-103 (ex vivo autologous gene therapy) Details X-Linked severe combined immunodeficiency, Autoimmune disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.